John Buse, MD, PhD; Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC
Robert Califf, MD; Duke Translational Medicine Institute and Division of Cardiology, Duke University Medical Center, Durham, NC
Niteesh Choudhry, MD, PHD; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Scott Connor, BS, Acurian, Inc., Horsham, PA
Jeffrey Curtis, MD, MS, MPH; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Susan Ellenberg, PhD; Center for Clinical Epidemiology and Biostatistics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Stephen Fortmann, MD; Center for Health Research Northwest, Kaiser Permanente Northwest, Portland, OR
Kenneth Hornbuckle, DVM, MPH, PhD; Office of Risk Management and Pharmacoepidemiology, Global Patient Safety, Eli Lilly and Company, Indianapolis, IN
Gabriella Lavezzari, PhD, MBA; Scientific Affairs, Pharmaceutical Research and Manufacturers of America, Washington, DC
Elliott Levy, MD; Global Pharmacovigilance and Epidemiology, Bristol-Meyers Squibb Co., Princeton, NJ
Leanne Madre, JD, MHA; Clinical Trials Transformation Initiative, Durham, NC
Elizabeth Mahon, JD; Johnson and Johnson, New Brunswick, NJ
Edward Mannello, RPh, MBA; AstraZeneca, Wilmington, DE
J. Stephen Mikita, JD; Clinical Trials Transformation Initiative, Patient Representative, Steering Committee, Salt Lake City, UT
Alvin Mushlin, MD, ScM; Weill Cornell Medical College, Department of Public Health, New York, NY
Vinit Nair, BSPharm, MS, RPh; Humana: Competitive Health Analytics, Inc. Louisville, KY
Jane Perlmutter, PhD; Clinical Trials Transformation Initiative, Patient Advocate, Ann Arbor, MI
Bruce Psaty, MD, PhD; University of Washington, Seattle, WA
Stephen Rosenfeld, MD, MBA; Quorum Review IRB, Seattle, WA
Claire Spettell, PhD; Aetna: Aetna Informatics, Blue Bell, PA